Eptifibatide bolus dose postductal stenting intervention: A single-center experience

Area of Science:

• Neonatal cardiology
• Interventional cardiology
• Pharmacology

Background:

• Stent thrombosis post-ductal stenting is a severe complication with high mortality.
• Oral antiplatelet drugs have inconsistent effects in critically ill neonates.
• Intravenous (IV) glycoprotein IIb/IIIa inhibitors (GPIs) offer rapid and potent antiplatelet effects.

Purpose of the Study:

• To evaluate the safety and efficacy of IV eptifibatide as a prophylactic agent against stent thrombosis in neonates.
• To assess bleeding complications and platelet counts following IV GPI administration.

Main Methods:

• A study involving 127 neonates undergoing ductal stenting procedures.
• Administration of an IV eptifibatide bolus (180 µg/kg) post-procedure.
• Monitoring for stent thrombosis, bleeding events, and platelet counts.

Main Results:

• One case of stent thrombosis occurred in the treated group.
• Five patients experienced bleeding complications.
• Eight patients developed thrombocytopenia; no significant impact on renal or liver function was observed.

Conclusions:

• IV GPIs are safe for neonates undergoing ductal stenting when used adjunctively with oral antiplatelet therapy.
• Age and renal function are critical factors for determining appropriate dosing.
• Randomized trials are necessary to confirm efficacy and compare with existing anticoagulation strategies.